GPCR
NASDAQStructure Therapeutics Inc.
Price$41.26-1.19 (-2.80%)
01:30 PM07:45 PM
News · 26 weeks45-37%
2026-03-152026-09-06
Mix2290d
- Insider14(64%)
- SEC Filings4(18%)
- Other2(9%)
- Leadership1(5%)
- Earnings1(5%)
Latest news
25 items- SECStructure Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight ManagementACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027 Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates due to adverse events in the ACCESS OLE clinical trial ACCOMPLISH-1 an
- PRStructure Therapeutics to Participate in Upcoming Healthcare Investor ConferencesSAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September: 2026 Cantor Global Healthcare ConferenceDate: Thursday, September 10Format: Fireside chat and 1x1 meetingsTime: 3:55 – 4:25 PM EDTLocation: New York, NY Morgan Stanley 24th Annual Global Healthcare ConferenceDate: Wednesday, September 16Format: Fireside chat and 1x1 meetingsTime: 10:45 – 11:20 AM EDTLocation: New York, NY Bernstein’s 3rd Annual H
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen exercised 17,817 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen exercised 11,817 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERChief Commercial Officer Berrios John Joseph was granted 140,766 units of Ordinary Shares (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 3 filed by new insider Berrios John Joseph3 - Structure Therapeutics Inc. (0001888886) (Issuer)
- SECSEC Form 10-Q filed by Structure Therapeutics Inc.10-Q - Structure Therapeutics Inc. (0001888886) (Filer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsFirst patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual amylin and calcitonin receptor agonist) and initiation of MAD clinical trial on track for Q3 2026 Topline 72-week aleniglipron ACCESS OLE data on track for Q3 2026; data from body composition, type 2 diabetes/obesity and SWITCH clinical trials on track for Q4 2026 Appointed metabolic commercial industry veteran John Berrios as Chief Commercial Officer Cash, cash equivalents and short-term investments of $1.3 billion as of June 30, 2026 expected to fund projected operations an
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen exercised 11,817 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by See Remark 1 Fmr Llc4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen exercised 23,634 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen exercised 23,634 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Director Russell Angus C.4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Director Love Ted W4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Director Waldstreicher Joanne4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Director Dobmeier Eric4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Director Tetlow Sharon4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Director Welch Daniel G4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for ObesityPublication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist Publication and presentation detail dose-dependent, clinically meaningful and statistically significant reductions in body weight with continued weight loss beyond 36 weeks, up to 16.2% during the open-label extension Aleniglipron safety profile reflects well-known GI-related GLP-1 class adverse events, with favorable tolerability profile demonstrated by an overall low (10.4%) discontinuation rate Phase 3 program remains on track to initiate in Q3 2026 Additional p
- PRStructure Therapeutics Announces Participation in Upcoming Investor ConferencesSAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June: 2026 Jefferies Global Healthcare Conference Format:Fireside chat and 1x1 meetings Date/time:Wednesday, June 3 at 12:15 p.m. ET Location:New York, NY Goldman Sachs 47th Annual Global Healthcare Conference Format:Fireside chat and 1x1 meetings Date/time:Tuesday, June 9 at 10:00 a.m. ET Location:Miami, FL The live and archived webcasts will be accessible from
- SECSEC Form 10-Q filed by Structure Therapeutics Inc.10-Q - Structure Therapeutics Inc. (0001888886) (Filer)
GPCR FAQ
6 questionsWhere does GPCR stock trade?
Structure Therapeutics Inc. (GPCR) is listed on NASDAQ.What sector and industry is GPCR in?
Structure Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Structure Therapeutics Inc. go public?
Structure Therapeutics Inc. (GPCR) completed its IPO in 2023.What are analysts saying about GPCR?
Structure Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-04-27.What companies are similar to GPCR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GPCR side-by-side with any of them on Quantisnow.How can I track GPCR on Quantisnow?
Quantisnow aggregates Structure Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GPCR to receive live email and push alerts on every new disclosure.